Inhaled therapeutics for prevention and treatment of pneumonia - Wikidata - wikimedia - TriplyDB

Inhaled therapeutics for prevention and treatment of pneumonia

Inhaled therapeutics for prevention and treatment of pneumonia

http://www.wikidata.org/entity/Q35925366

about

Pseudomonas aeruginosa ventilator-associated pneumonia management Characterization of a human powered nebulizer compressor for resource poor settings.Effect of formulation on the stability and aerosol performance of a nebulized antibody Extracellular matrix lumican promotes bacterial phagocytosis, and Lum-/- mice show increased Pseudomonas aeruginosa lung infection severity.Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.Immunomodulatory properties of antifungal agents on phagocytic cells.Mechanisms of absorption and elimination of drugs administered by inhalation.Acute myeloid leukemia and the infectious diseases consultant.Inducible epithelial resistance protects mice against leukemia-associated pneumonia.Lung epithelial cells are essential effectors of inducible resistance to pneumonia.In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates.Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention.Beatmungsassoziierte Pneumonie bei Kindern

P2860

Q26768365-459FB800-4E80-4A4F-8CC8-FA3CE3845231 Q33818225-1EDDE80D-E9B8-4677-92CD-1A4B8D75D7B0 Q35526961-980C3DFC-8544-425B-84A5-83F42F8E9781 Q36332751-ADF2C2D0-8875-447D-BC50-7DAE987D52C7 Q36755190-2D8F1FEE-4234-45FA-B8C0-7A5B0E0B30A4 Q37216741-FDDED3DF-7F99-4A8D-B35A-0538C0FA0121 Q37943851-FF3A121A-B290-4298-A83F-6A394EAADC1F Q38126941-8A6B3911-E6F0-4FB1-9B74-E9E9A0A83221 Q40039262-0040FEFE-7E3B-4BBF-8BFD-95698C59BFCE Q41563226-043948A5-F09E-4438-8D39-A967E51E42C9 Q42264726-C04B3398-EA5A-482E-B308-0FA231C33121 Q47547837-29EA1C5B-A306-401F-BF61-8CC8BD3C533E Q55514832-1EBE6736-43B2-4257-8A92-5B41B97AA0A1 Q58896436-32B20DDE-4042-4A03-8DC9-4E3C8B3B87FF

P2860

Inhaled therapeutics for prevention and treatment of pneumonia

http://www.wikidata.org/entity/Q35925366

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Inhaled therapeutics for prevention and treatment of pneumonia

@ast

Inhaled therapeutics for prevention and treatment of pneumonia

@en

type

label

Inhaled therapeutics for prevention and treatment of pneumonia

@ast

Inhaled therapeutics for prevention and treatment of pneumonia

@en

prefLabel

Inhaled therapeutics for prevention and treatment of pneumonia

@ast

Inhaled therapeutics for prevention and treatment of pneumonia

@en

P1433

Q35925366-5F6B7939-1157-409D-94A5-A3D90C79CE04

P1476

Q35925366-E50896E4-B2D7-4EC4-B9D5-2F156DBDC945

P2093

Q35925366-4B6066AC-391F-41CC-8D85-6FAAE3E4B2CF

Q35925366-660477FD-CBDA-4421-9656-4959B80174F3

Q35925366-EF9A19F5-F49D-498B-B230-BD332DA9D122

P2860

Q35925366-0278349D-BB9A-488B-B978-D7033F1E52D9

Q35925366-09A666DD-B744-4B31-91C2-03F7658D7809

Q35925366-0AA2E00F-7858-4E6C-9AC7-6DCD958409F5

Q35925366-0BA0E7E1-9897-4DB3-9BA0-2119D70A65AD

Q35925366-0BD9C033-D22F-43D1-AD5B-8B08BA21A61B

Q35925366-0C38F5D1-78E4-46B3-AB41-326A2B2787B1

Q35925366-0C9BBC76-9FF0-4F4D-B0B3-AC61D4B95068

Q35925366-1292E95A-8DFD-4D2C-A17A-9642F510EC1B

Q35925366-145B1F96-47E4-498A-8BEC-5AFB1CFC87BC

Q35925366-146FFF90-1058-45F8-AD0D-C022479EF817

P304

Q35925366-6ADE7EF6-A94A-445D-A793-BA4E860D2D13

P31

Q35925366-3B537CC4-CAA8-4EA0-A12B-EB4DCBF58E0B

P356

Q35925366-52BBD581-7B27-4BD5-AF23-853F88931593

P407

Q35925366-F2718DD4-D4E3-447C-96F6-CA060447E810

P433

Q35925366-15C04D1A-B65B-407B-A1D4-AC053D2B5848

P478

Q35925366-35869C29-9FF5-4867-85BE-4A4F3AA3211F

P50

Q35925366-50825934-CFE5-4110-AB52-318850498D06

P577

Q35925366-8BE2F1F9-20CC-4242-87F8-F45E642FA299

P5875

Q35925366-1099CA14-F064-4385-85F4-A554DAFC40FE

P698

Q35925366-859709A8-AB5E-464B-B254-8FC44D1B5188

P932

Q35925366-1AA45D79-86AD-4192-80A4-16D75FA096A5

P356

14740330903036083

P1433

Expert Opinion on Drug Safety

P1476

Inhaled therapeutics for prevention and treatment of pneumonia

@en

P2093

Amar Safdar

http://www.w3.org/2001/XMLSchema#string

Samuel A Shelburne

http://www.w3.org/2001/XMLSchema#string

Scott E Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Breakdown of Pulmonary Host Defense in the Immunocompromised Host: Cancer Chemotherapy

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

Nebulised hypertonic saline for cystic fibrosis

Antimicrobial proteins and polypeptides in pulmonary innate defence

Cystic fibrosis

Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation

beta-Defensin 1 contributes to pulmonary innate immunity in mice

Sverdlovsk revisited: modeling human inhalation anthrax

Recognition of microorganisms and activation of the immune response

P304

435-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740330903036083

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Burton F Dickey

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26302979

http://www.w3.org/2001/XMLSchema#string

P698

19538104

http://www.w3.org/2001/XMLSchema#string

P932

4527977

http://www.w3.org/2001/XMLSchema#string